I’m going to be starting RT in September for my prostate and pelvic LN mets (2). My RO doesn’t want to use EBRT on my periaortic LN mets (2), he feels like they’re to near organs. I’m thinking of Cyberknife for those mets. I’ve had chemo and I’m on Lupron and Nubeqa. My last PSA was 0.055. I’m feeling pretty good physically. I’m meeting with my MO for a consultation in July and I’m planning to propose Cyberknife.
Any opinions or feedback you can share would be appreciated.
Written by
Peeffervescence
To view profiles and participate in discussions please or .
CyberKnife is EBRT. It is delivered in a more concentrated form than usual, so toxicity can be more of a problem, not less. Your RO has to make a judgment based on your personal anatomy. That high up, radiation can do a lot of damage, so be careful what you ask for.
Totally agree . Be careful.My retroperitoneal nodes have shrunk to where they are difficult to image, so not treating. On Lupron and Nubeqa also (5 and 2 years) and PSA is undetectable
I’m also on Eligard and Nubeqa (as well as having completed chemo). When we discussed my final radiation treatment plan after chemo we discussed being as aggressive as safely possible. My RO suggested not doing anything with my periaortic lymph nodes because he was concerned about the potential for too many side effects. He thought it was better to not irradiate them and see what the chemo / ADT / Nubeqa does and go back later only if needed. We ended up doing prostate / SV, all the lymph nodes / pelvic region up to about to spine L4 and my one bone met.
Get a third opinion. Also, consider getting an opinion from one of the best facilities like Mayo Clinic (in Rochester) You don’t usually get second chance on treatment so your choice now is paramount.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.